Morningstar
•
Oct 30, 2026
Penumbra, Inc.: Penumbra Earnings: Solid Quarterly Results as Firm Awaits Closure of Boston Acquisition
Summary
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Stryker Corporation
Oct 30, 2026
•
SYK
Analyst Report: West Pharmaceutical Services, Inc.
Oct 29, 2026
•
WST
Daily – Vickers Top Buyers & Sellers for 10/29/2026
Oct 29, 2026
•
MEDP, RS, R, AIR, TTMI, XBIT, ACN, BNY, HXL
Analyst Report: Boston Scientific Corporation
Oct 28, 2026
•
BSX
GKOS: Raising target price to $190.00
Oct 28, 2026
•
GKOS
Analyst Profile
Debbie S. Wang
Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.
